Foghorn Therapeutics Inc. filings document a clinical-stage biotechnology issuer with common stock listed on the Nasdaq Global Market under FHTX. The company’s current-event filings cover financial results, Regulation FD investor presentations, oncology pipeline disclosures for FHD-909 and selective CBP, EP300 and ARID1B degrader programs, and collaboration-related revenue.
Proxy and 8-K filings also address annual-meeting voting matters, board and executive governance, officer appointments, compensatory arrangements, material agreements, capital-structure disclosures and security-registration details tied to the company’s common stock and financing activity.
Foghorn Therapeutics Inc. director Ian F. Smith received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, contingent on his continued board service, and expire on June 23, 2036. Following this compensation award, Smith holds 28,000 options directly, and the filing reports no open-market buying or selling activity.
Foghorn Therapeutics Inc. director Simba Gill received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, subject to continued service on the board, and expire on June 23, 2036. Following this award, Gill holds 28,000 stock options directly.
Foghorn Therapeutics Inc. director Lynne B. Parshall received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $4.08 per share and expire on June 23, 2036. Following this grant, she holds 28,000 options directly. According to the terms, the option vests in full on the first anniversary of the grant date, assuming she continues to serve on the board of directors.
Foghorn Therapeutics director Douglas G. Cole received a compensation-related stock option grant. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, as long as he continues serving on the board. Following this grant, he holds 28,000 stock options, which are scheduled to expire on June 23, 2036.
Foghorn Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on June 24, 2026. Stockholders elected three Class III directors—Douglas Cole, M.D., Balkrishan (Simba) Gill, Ph.D., and B. Lynne Parshall—to serve until the 2029 annual meeting. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. On an advisory basis, stockholders approved the compensation of the company’s named executive officers and supported holding future advisory votes on executive compensation every one year. A total of 58,713,922 shares were entitled to vote, with 51,708,896 shares present or represented by proxy.
Foghorn Therapeutics Inc. Schedule 13G/A shows a group of Biotechnology Value Fund entities and Mark N. Lampert reporting shared beneficial ownership totals. As of the close of business on March 31, 2026, the Reporting Persons and a Partners managed account hold 3,164,410 shares through BVF, 2,218,382 shares through BVF2, and related aggregate positions that may be attributed across affiliated entities.
The filing also discloses 6,050,782 Pre-Funded Warrants exercisable for common stock (exercise price $0.0001), with a Pre-Funded Warrants Blocker limiting exercise to 24,613 shares. The Reporting Persons report aggregate Series 1 and Series 2 Warrants exercisable for 1,862,891 shares each, with exercise blocked by a Series Warrants Blocker. Percentages are calculated using 58,700,246 Shares outstanding as of February 27, 2026.
Foghorn Therapeutics reports amended Schedule 13G ownership disclosures showing 5,139,523 shares held by Deerfield-related reporting persons, representing 8.64% of common stock. The reported position comprises 4,394,367 issued shares and 745,156 shares issuable upon exercise of warrants.
The filing states the warrants contain an Ownership Cap that prevents exercise that would cause aggregate beneficial ownership to exceed 9.99%, and the reporting persons disclaim beneficial ownership to the extent the cap would be exceeded. Joint filing exhibits and a power of attorney are attached.
Foghorn Therapeutics reported a first-quarter 2026 net loss of $19.9 million, similar to the prior-year loss of $18.8 million, as it continues investing in its chromatin-targeting oncology pipeline.
Collaboration revenue from its Lilly partnership was $3.3 million, down from $6.0 million, while research and development spending decreased to $18.3 million and general and administrative costs fell to $6.6 million. Cash, cash equivalents and marketable securities totaled $183.6 million as of March 31, 2026, helped by a $50.0 million January 2026 direct equity and warrant financing. Management believes current liquidity will fund operations for at least 12 months, supported by $245.9 million of deferred revenue tied to the Lilly collaboration.
Foghorn Therapeutics reported first quarter 2026 results alongside a broad pipeline update in oncology. Collaboration revenue was $3.3 million for the three months ended March 31, 2026, while research and development expenses were $18.3 million and general and administrative expenses were $6.6 million.
The company recorded a net loss of $19.9 million for the quarter, or $0.29 per share, compared with a net loss of $18.8 million a year earlier. As of March 31, 2026, Foghorn held $183.6 million in cash, cash equivalents and marketable securities, which it expects will fund operations into the first half of 2028.
Operationally, Foghorn highlighted progress for its lead SMARCA2 inhibitor FHD-909, now in an ongoing Phase 1 trial in SMARCA4-mutant cancers under its collaboration with Lilly, and presented preclinical data showing promising combination effects with anti-PD-1 therapy and KRAS inhibitors. The company also advanced selective degrader programs targeting CBP, EP300 and ARID1B toward IND-enabling studies and in vivo proof of concept, underscoring a diversified pipeline in difficult-to-treat cancers.
FMR LLC filed an amendment to Schedule 13G/A reporting beneficial ownership of 6,792,356 shares of common stock of FOGHORN THERAPEUTICS INC. The filing shows this equals 11.6% of the class and identifies the CUSIP 344174107. The cover indicates the reporting period 03/31/2026. The filing states certain voting and dispositive powers held by FMR LLC and by Abigail P. Johnson as reported, and references an attached 13d-1(k)(1) agreement in Exhibit 99.